BridgeBio Oncology Therapeutics, Inc. (BBOT) earnings
Quarterly results of BridgeBio Oncology Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
BridgeBio Oncology Therapeutics, Inc. was expected to report around November 10, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) BridgeBio Oncology Therapeutics, Inc. reported revenue of - and a net loss of $56.5M.
Diluted earnings per share were -$705.20.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | - | - | -$56.5M | -$705.20 |
| Q1 FY2026 | - | - | -$42.1M | -$526.11 |
| Q4 FY2025 | - | - | -$38.8M | - |
| Q3 FY2025 | - | - | -$44.8M | -$1.03 |
| Q2 FY2025 | - | - | -$28.4M | -$566.46 |
| Q1 FY2025 | - | - | -$22.1M | -$54.23 |
| Q4 FY2024 | - | - | -$19.7M | - |
| Q3 FY2024 | - | - | -$17.3M | -$1,562.18 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
- Annual report 10-K
- Quarterly results 8-K
When is BridgeBio Oncology Therapeutics, Inc.'s next earnings date?
BridgeBio Oncology Therapeutics, Inc. was expected to report around November 10, 2026; nothing is on file with the SEC yet.
Get an email when BBOT reports
Follow BBOT and we email you its next results the day they are filed, with the numbers explained.